We raised monoclonal antibodies (MAb) against the core protein and the heparan sulfate (HS) side chain of heparan sulfate proteoglycan (HSPG) from glomerular basement membranes (GBM). Anti-HSPG-core MAb were obtained after immunization of mice with HSPG p d i e d h m human GBM and the anti-HS MAb &er immunization of mice with HSPG from rat glomeruli, which crossreacted with human HS and GBM HSPG. The specificity of the MAb was demonstrated by ELISA studies, Western blotting, inhibition experiments, and indirect immunofluorescence (IF) on kidney cryostat sections pre-treated with glycosaminoglycan (GAG)-degrading enzymes. Indirect IF on normal human kidney tissue showed prominent GBM staining for both MAb, with variable staining of the other renal basement membranes (BMs). By indirect immunoelectron microscopy (EM), most intense staining was observed at the endothelial side of the GBM for both
Introduction
Proteoglycans (PGs) are macromolecules with a ubiquitous tissue distribution. They are composed of glycosaminoglycan (GAG) chains covalently attached via a linkage structure to a protein core (22,26,63). One class of PGs is formed by the heparan sulfate PGs (HSPGs), which are found both on cell surfaces and in basement membranes (BMs) (20). Cell surface-associated HSPGs are either integral plasma membrane proteins or peripheral membrane components bound to the cell surface by specific receptors or through a glycosyl-phosphatidylinositol anchor (12 ~9 ) .
They have been strongly implicated in roles in cell recognition, cell adhesion, cell Supported by a grant (86.616) MAb, although the staining patterns were not identical. Both MAb were used to localize HSPG in human tissues by indirect IF. They bound to antigens present in the BMs of most tissues examined, including those of epithelia and endothelia. Differences between both MAb were observed for BMs of muscle cells, since the anti-HSPG core.protein MAb (JM-72) staining was nega&, whereas the anti-HS MAb (JM-403) clearly stained these structures. Comparison of our staining patterns in human tissues with the distribution of other anti-BM HSPG antibodies suggests that there are at least two types of BM HSPG, which have common epitopes on the HS side chains recognized by JM-403. ( J Histochem Cytochem 42:89-102, 1994) migration, and cell growth (28,30,45,61,76) . HSPGs in BMs, notably those in the glomerular basement membrane (GBM), are believed to control the charge-dependent permeability of the GBM by virtue of their anionic charge provided by the HS side chains (6,18,35). After enzymatic removal of HS from the GBM, the glomerular capillary wall loses its ability to restrict the passage of albumin (62). Moreover, clinically and experimentally, a reduction of (primarily HS associated) anionic sites is characterized by the appearance of proteinuria (3,21, 47, 55, 57, 67, 83) . Both classes of HSPGs mentioned above are, immunologically and structurally, completely different. Antibodies against one HSPG class do not crossreact with the other (32,71). Moreover, the primary structures of cell surface-associated HSPGs, such as glypican (12) or members of the syndecan family (4,39,43,49,51,58,65) , differ from those of the large BM HSPG (14,34,56 ). In addition, the chromosomal localization is different, as the gene coding for the human cell-surface 89 HSPG fibroglycan is located on chromosome 8 (51) , whereas the gene for the human BM HSPG has been localized to chromosome 1 (14, 33, 86) . For further characterization of function and distribution of HSPGs, monoclonal antibodies (MAb) can provide important tools. We have previously reported about the production of an MAb recognizing the HS side chain of HSPG (78) .
Here we describe the production and Characterization of an MAb UM-72) against the core protein of human GBM HSPG. The presence of HSPG core protein was studied immunohistochemically in a variety of human tissues and was compared with a new anti-HS MAb, JM-403, which we described recently (77). The results of these studies indicate heterogeneity of the diverse tissue BMs and suggest the existence of several types of BM HSPGs.
Materials and Methods

Proteoglycans and Glycosaminoglycans
Human GBM HSPG was isolated and characterized as described previously (80) . Briefly, GBMs were prepared from human kidneys by the detergent method and HSPG was pursed under dissociative conditions by 4 M guanidine extraction, ion exchange and gel permeation chromatography. The core protein of GBM HSPG was prepared according to the procedure of Edge et al. (15) with some minor modifications (SO), using trifluoromethanesulfonic acid (TFMS) as deglycosylating agent. Rat glomerular HSPG was partially purified under dissociative conditions by 4 M guanidine extraction and ion exchange chromatography (77). Dermatan sulfate proteoglycan isolated from bovine lung (82) was kindly provided by Dr. A. van Kuppeveld (Dept. of Biochemistry, University of Nijmegen, The Netherlands). Chondroitin sulfate, dermatan sulfate, and keratan sulfate proteoglycans isolated from bovine hyaline cartilage were a generous gift of Dr. R. van de Stadt (Jan van Breemen Institute, Amsterdam, The Netherlands). The following GAGS were used: HS isolated from bovine kidney (Seikagaku; Tokyo, Japan); chondroitin sulfate A and C isolated from whale cartilage (Sigma; St Louis, MO); dermatan sulfate isolated from porcine skin (Sigma); keratan sulfate isolated from calf cartilage (donated by Dr. R. van de Stadt), heparin (Thromboliquine; Organon Teknika, Oss, The Netherlands) and hyaluronic acid (HA) isolated from human umbilical cord (Sigma). Heparitinase (Seikagaku) was used at a concentration of 1 Ulml, chondroitinase ABC (Sigma) at 0.1 Ulml, and hyaluronidase (Sigma) at 50 Ulml.
Hybridoma Production
Female Balblc mice were immunized IP at Days 0 and 30 with 50 pg human GBM HSPG or with 50 pg of rat glomerular HSPG in 0.2 ml PBS emulsified with 0.2 ml complete Freund's adjuvant. At Days 60, 61, and 62 the mice were boosted IV with 15 pg HSPG in 0.15 liter PBS. At Day 63 mice were sacrificed, blood was taken, and the spleen cells were isolated and fused with the non-producing mouse myeloma cell line SP2l0 according to Kohler and Millstein (42) with some minor modifications. Syngeneic peritoneal macrophages (10,000-20,000 cellslwell) were used as feeder layer. Wells with growing hybridomas were screened in ELISA for anti-HSPG and anti-HS reactivity and by indirect immunofluorescence (IF) on human or rat kidney cryostat sections. After HAT selection, cell cultures were grown in HEPES-buffered RPMI-1640 culture medium containing 10% fetal calf serum, gentamycin (40 pglml), pyruvate (110 pglml), and glutamine (292 pglml) and cultured in a humidified incubator at 37'C with 95% air and 5 % CO2. Selected wells were recloned by limiting dilution until all subclones showed the same reactivity pattern. The antibody subclass was de-termined in ELISA using subclass-specific antibodies conjugated to peroxidase (Southern Biotechnology Associates; Birmingham, AL). Female Balblc mice pre-treated with pristane (2,6,10,14-tetramethylpentadecane 96%) Uanssen Chimica; Beerse, Belgium) were injected IP with 3 x lo6 viable hybridoma cells. After 2-4 weeks ascites was drained, centrifuged to remove cells, clotted overnight at 4'C, filtered through 0.2-pm filters, and stored at -2O'C until use. Antibody concentration in the ascites was determined by single radial immunodiffusion (30).
Characterization of MA6
ELISA Studies. Anti-HS reactivity was measured in ELISA as described (17), using aprotamine chloride pre-coating to bind the negatively charged HS to the plates. Antibody reactivity against human GBM HSPG, rat glomerular HSPG, laminin from human placenta (Calbiochem; La Jolla, CA) or from the mouse Engelbreth-Holm-Swarm (EHS) tumor (Sigma), collagen Type IV from human placenta or from the mouse EHS tumor (Sigma), fibronectin from human plasma (Sigma) or from rat plasma (Calbiochem) and several other PGs was tested in ELISA according to Rennard et al. (60) . Positive controls used in the ELISA studies were MAb against human laminin (Calbiochem), rabbit anti-mouse EHS laminin (Gibco Europe; Breda, The Netherlands), MAb against human collagen Type IV (23) (kindly provided by Dr. J.P.M. Cleutjens, University of Limburg, Maastricht, The Netherlands), rabbit anti-mouse EHS collagen Type IV (Collaborative Research; Bedford, MA), rabbit anti-human fibronectin (Calbiochem), goat anti-rat fibronectin (Calbiochem), rabbit anti-bovine dermatan sulfate PG (82) (kindly provided by Dr. A. van Kuppeveld), and rabbit anti-human GBM HSPG, prepared as described (80) .
Inhibition Experiments. A constant amount of MAb giving 50% of the maximal ELISA signal was added to an increasing concentration of inhibitor (0.2-200 pglml) and incubated for 1 hr at 37'C and subsequently for 1 hr at 4°C to optimize immune complex formation. This mixture was added to ELISA plates pre-coated with GBM HSPG or HS. Bound antibodies were developed as described for the ELISA. Percentage inhibition was calculated as:
Western Blotting. Intact GBM HSPG or its core protein was run on 3-20% SDS-PAGE and blotted overnight to nitrocellulose (75). After incubation with the primary antibodies and development with peroxidaseconjugated goat anti-mouse IgG, heavy and light chain specific (Nordic; Tilburg, The Netherlands), blots were stained with 4-chloro-l-naphthol(24).
Immunohistochemical Techniques
Indirect Immunofluorescence. Human tissue specimens were obtained during autopsy or surgery, snap-frozen in liquid nitrogen, and stored at -70°C. Two-pm cryostat sections of these tissues were fixed for 5 min in acetone and washed with PBS. Thereafter, 100 pl of diluted ascites (1:200 for both JM-72 and JM-403 in PBS containing 1% BSA and 0.05% sodium azide) was applied to the sections for 30 min at room temperature (RT). After washing with PBS, binding of JM-72 (anti-GBM HSPG core) and JM-403 (anti-HS) was visualized with F(ab)2 fragments of FIT-labeled sheep anti-mouse IgG, heavy and light chains (Cappel-Organon Teknika, Turnhout, Belgium), 100 p1 diluted 1:500, or FITC-labeled goat anti-mouse IgM, Fc-specific (Nordic), 100 p1 diluted 1:lOO in PBS containing 1% BSA and 0.03% sodium azide, respectively. After incubation for 30 min at RT in the dark, sections were washed with PBS, embedded in Aqua Mount, and examined with a Zeiss Axioskop microscope fitted for fluorescence microscopy. All incubations were done with the same batches of MAb and 
Results
Immunoelectmn Microscopy. Two human cadaver donor kidneys, not suitable for transplantation. were perfused wirh Eurocollins solution and kept on ice for 16 and 36 hr. For indirect IEM the kidneyswere subsequently perfused with a mixture of periodate-lysine-2% paraformaldehyde (PLP) fixativc for 15 min. Small pieces of renal cortex were further immersed in the same fixarive for an additional 1.5 hr, cryoprotected in 2.3 M sucrose for 1 hr. and snap-frozen in liquid nitrogen. Twenty-pm cryostat sections were incubated with MAb IM-72 diluted 1:200 in PBS containing I% BSA
Pmduction and Characterization Of Anti-human GBM HSPG M&
After immunization of female Balblc mice with human GBM HSPG, we obtained 18 MAb against this PG. of which the charactcristics Of One repracntativc MAb of this group* JM-7*9 are Presented. This antibody is ofthe kGl S U b c h~. AScit~contained 10 mg IgGi Iml. In ELI% MAb JM-72 bound to human GBM or with MAb JM-403 dilured 1970 in PBSIl% BSA for 18 hr at 4%. After three washes in PBS-1% BSA the secrions were immunolabeled by incubation with a peroxidase-labeled rabbit ami-mouse Ig (Dakopatts; Copenhagen, Denmark) diluted 1:20 in PBS-I% BSA for 2 hr. After xvcral washes in PBS-1% BSA the sections were incubated with 0.05% diaminobenzidine medium conraining 0.6% Tris for 10 min. followed by DAB with addition of 7 pI of 30% H202 for 7 min. Afrer three washa in disrilled warer the secrions were post-fixed in 0.1 M phosphate-buffered 1% 0~0 4 , pH 7.4, for I5 min at RT. dehydrated. and embedded in Epon 812. Thin sections were prepared on an LKB Ultntome and examined in a Jeol 1200 EX II electron microscope. Control experimenrs were performed with nonrelevant isotype-matched MAb in the same Ig concentration. HSPG and to its core protein obtained after removal of HS by TFMS but not to HS ( Figure 1A) . The reactivity towards the HSPG core protein was eight t i m a stronger than to the total HSPG molecule. No reactivity could be observed in ELISA with other BM components such as laminin, fibronectin, and collagen Type IV (all of human origin), nor was any reactivity dctmable towards chondroitin sulfate. keratan sulfate. and keratan sulfate PGs ( Figure 1A) . With a non-relevant MAb of the same isotypc and immunoglobulin concentration, no binding was observed to HSPG (data not shown). Binding ofJM-72 to GBM HSPG in ELISA could specifically and dose-dependently be inhibited by GBM HSPG and by its core pro- tein ( Figure 1B) . HS, laminin, fibronectin, and collagen Type IV, as well as chrondroitin sulfate, dermatan sulfate, and keratan sulfate PGs had no effect on binding of MAb JM-72 to GBM HSPG in the inhibition ELISA. As in the direct ELISA,JM-72 displayed in the inhibition ELISA a greater affinity for the HSPG core protein than for the total HSPG molecule, since 50% inhibition was obtained, respectively, with 18 and 132 pg/ml. These results indicate that MAb JM-72 is directed against an epitope located on the core protein of human GBM HSPG. This specificity could be confirmed by Western blotting. With intact HSPG (Figure 2A ), one major broad band with a molecular mass between 200-400 KD was revealed after staining. Treatment of the PG with TFMS resulted in several bands with molecular masses of 160, 110, 90, and 60 KD ( Figure 2B ). The presence of core proteins with different molecular masses after TFMS treatment of HSPG either indicates the existence of core proteins with variable molecular masses or may be due to proteolytic cleavage of the precursor protein. These results are identical to those we reported previously (80) . The intact HSPG and its core proteins stained clearly with MAb JM-72 (Figure 2A , Lane 2 and Figure 2B , Lane 2, respectively). A 1:50 dilution of the mouse serum, which was chosen for hybridoma production and known to be positive in ELISA and indirect IF, served as a positive control (Figures 2A and 2B , Lane 1). As can be seen in Figure 2A , Lane 1, the mouse serum reacts with two additional bands with a lower molecular weight. At present we do not know the identity of these bands, which are not visualized by MAb JM-72 or a previously prepared polyclonal rabbit anti-GBM HSPG antiserum (80) (data not shown 
Production and Characterization of Anti-HS MA6
After immunization with a rat glomerular HSPG preparation, one anti-HS MAb of the IgM isotype (JM-403) was obtained (77). Ascites obtained after IP inoculation of hybridoma cells contained 6.5 mg IgM/ml. The reactivity pattern of MAb JM-403 in ELISA is shown in Figure 3A . Clear reactivity was observed with HS, but no binding occurred to chondroitin sulfate A and C, dermatan sulfate, keratan sulfate, or heparin. Furthermore, the MAb bound to human GBM HSPG but not to its core protein ( Figure 3A) . With a non-relevant MAb of the same isotype and immunoglobulin concentration, no binding was observed to HS. The specificity of MAb JM-403 was confirmed by inhibition ELISA, shown in Figure 3B . Both HS and intact GBM HSPG inhibited the binding of MAb JM-403 to HS in a dose-dependent manner, whereas the HSPG core protein and the other GAGs did not show any inhibition. Since the same GBM HSPG core protein preparation was used for this experiment as for the inhibition of JM-72 (Figure lB) , we could exclude denaturation or degradation of the core protein as a cause for the lack of inhibitory effects ofJM-403 binding to HS. In addition to binding to HS, JM-403 showed a crossreactivity with hyaluronic acid (HA) in ELISA, which we have described previously (77). However, we have subsequently found that treatment of HA with HN02 or heparitinase (methods to destroy specifically HS) completely abolished the binding ofJM-403 to HA, whereas treatment of HA with hyaluronidase (to destroy specifically HA) did not alter the binding of MAb JM-403 to this preparation (data not shown). These results indicate that the HA preparation is contaminated with HS. Our attempts to perform staining in a Western blot with JM-403 on intact HSPG and its core protein were unsuccessful. Whether this is due to destruction of the JM-403 epitope by the SDS treatment is not yet known.
HSPG and HS Distribution in Human Kidney Tissue
In the indirect IF, MAb JM-72 (anti-HSPG core) showed in the glomerulus a brilliant linear staining of the GBM, whereas the mesangial matrix was negative ( Figure 4A) . the smooth muscle cells in arterial walls) ( Figure 4B ). No interstitial staining was observed. The results of the indirect IEM on normal kidney tissue originating from two unrelated individuals confirmed the findings of the indirect IF. Staining was observed throughout the whole GBM but the reaction product was more prominent at the endothelial side of the GBM (Figures 5A and  5B) . The mesangial matrix did not stain, although there was slight staining at the border between the mesangium and the capillary endothelium ( Figure 5A, arrows) . All tubular BMs were stained as well as the BMs of the peritubular capillaries (not shown). No specific staining was observed in the control experiments using a non-relevant IgGl MAb in the same Ig concentration ( Figure 5C ). After indirect IF on human kidney tissue, anti-HS MAb JM-403 displayed a homogeneous staining of the GBM ( Figure 4C ). Other renal BMs stained with variable intensity. The BMs of peritubular capillaries and those of vascular smooth muscle cells were strongly positive, endothelial BMs of venules and arteries and Bowman's capsule were moderately positive, and tubule BMs ranged from negative to positive ( Figure 4D ). Pre-treatment of cryostat sections with 1 Ulml heparitinase prevented all JM-403 staining, whereas pre-treatment of the sections with chondroitinase ABC and hyaluronidase did not influence the binding of the MAb. This was also found in tissues known to contain large amounts of HA (skin and umbilical cord), indicating that HA was not recognized in situ (results not shown). In indirect IEM, incubation with MAbJM-403 predominantly revealed staining of the subendothelial side of the GBM (Figures 5D and 5E) . As for the anti-HSPG-core MAb, this anti-HS MAb also stained the border between the mesangium and the glomerular endothelial cells (Figure SD, arrows) . As in the indirect IF the BMs of the peritubular capillaries were positive and the tubule BMs were negative (proximal tubules) or positive (not shown). Control experiments using a non-relevant IgM MAb in the same IgM concentration revealed no renal staining at all ( Figure 5F ).
HSPG ana' HS Distribution in Non-rend Human Tissues
To localize the expression of GBM HSPG and HS throughout the body, a panel of human tissues was investigated with both anti-HSPG MAb (anti-HSPG core MAb JM-72 and anti-HS MAb JM-403). The results are summarized in Table 1 Figures 6A-6D and 6A-6D). The staining pattern observed in tissues of the lower gastrointestinal tract was variable. We analyzed tissue specimens of the stomach, small intestine, and colon from three different sources. Only one specimen of the stomach and one of the colon clearly stained with MAb JM-72, whereas in all three occasions the staining in the small intestine was negative. However, all of these tissues (including the small intestine) clearly stained with a polyclonal antiserum against human GBM HSPG core protein and with anti-HS MAb JM-403, pointing to the presence of HSPG in these tissues. This indicates that the epitope recognized by JM-72 on the HSPG core protein is either absent or has a variable expression.
In the liver, anti-HS MAb JM-403 bound to the sinusoidal wall (sometimes in a segmental fashion), whereas MAb JM-72 staining was very weak (Figures 6E and 6E ). In the same sections, the BMs of the blood vessels and bile ducts were positive with both MAb. All endothelial BMs of blood vessels, ranging from large to small, arterial as well as venous, capillaries, and sinuses stained with both MAb, although MAb JM-403 staining was much more prominent (Table 1; Figure 6 ). Although MAb JM-403 clearly recognized basal lamina-associated HS of myocardial muscle cells as well as those of all skeletal and smooth muscle cells throughout the body, anti-HSPG core MAb JM-72 stained only the basal laminae of smooth muscle cells belonging to the arterial wall. Basal laminae of smooth muscle cells elsewhere in the body (e.g., in gastrointestinal tract, skin, prostate, and urinary bladder) and those of skeletal and myocardial muscles were not recognized by MAb JM-72 ( Figures 6F and  6G, 6F and 6G') . The basal laminae of Schwann cells in the peripheral nerves (as observed in skeletal muscle) were positive with MAb JM-72 but stained very weakly with MAb JM-403. In the brain (cerebrum and cerebellum), only immunostaining of the blood vessels was obtained. In lymphatic tissue (spleen, thymus, tonsil, lymph node) the BMs of blood vessels, sinuses, and the interlobulary connective tissue stained with both MAb. No staining of the sections was observed with non-relevant IgGl and IgM MAb developed with their respective FIX-labeled conjugates. Taken together, these results indicate that both MAb stained exclusively BM-associated HSPG throughout the body, although JM-72 distribution is more limited compared with JM-403, especially in muscle tissues. The staining of the BMs in the tissues could be completely inhibited when the sections were incubated by the MAb in the presence of purified GBM HSPG. Cell surface-associated HSPG was not recognized by both MAb, indicating that the epitopes recognized by these MAb are not present on cell surfaceassociated HSPG core protein and HS chains.
Discussion
In this study the production and characterization of MAb reacting with the core protein UM-72) or the HS chains UM-403) of human GBM HSPG is described. These MAb were used to study immunohistochemically the co-localization of GBM HSPG core protein and GBM HS in human tissues.
Characteristics of the MA6
The results obtained in the ELISA, the inhibition studies, and the Western blotting indicate that MAb JM-72 is directed against the core protein of GBM HSPG. In the ELISA and in the inhibition experiments, JM-72 showed a higher reactivity with the HSPG core protein than with the total HSPG molecule, suggesting that glycosylation of the core protein decreases the binding of MAb JM-72 to its epitope. Similar results were obtained by Couchman and Ljubimov (9) with MAb against EHS-derived HSPG core protein.
Whether this enhanced binding is due to steric hindrance of the epitope on the core protein by the presence of the HS molecules or to increased expression of the epitope after deglycosylation is not yet known. The HS specificity of MAb JM-403 was demonstrated in ELISA, inhibition experiments, and in indirect IF after pre-treatment with GAG-degrading enzymes. Although we described previously that MAb JM-403 also bound to HA, we now know that this crossreactivity is due to contamination of the HA preparation with HS. This finding is corroborated by the fact that tissues rich in HA (such as skin and umbilical cord) were not stained by JM-403 except for the HS-containing BMs.
HSPG Core Protein Distribution in Human Tissues
We observed variable staining intensity with MAb JM-72 in the dLfferent BMs (Titable 1). This may be due to differences in the HSPG content, to differences in the accessibility of the JM-72 epitope by steric hindrance of other BM components, or to variations in the degree of glycosylation of the HSPG core protein. The IF pattern observed with our anti-GBM HSPG core MAb JM-72 resembles those reported by other investigators in rat and human tissues using anti-HSPG antibodies (7, 38, 48, 53, 66, 80 ) (Eble 2). As shown in Table 2 , this distribution pattern is observed with antibodies obtained after immunization with a small high-density HSPG mainly of glomerular or GBM origin. This is in contrast to the staining pattern observed with antibodies directed against a large low-density HSPG mainly derived from the mouse EHS tumor or against HSPG derived from other sources but immunologically related to EHS HSPG (9, 16, 27, 37) . With these latter antibodies the most prominent staining in the kidney was seen in the mesangium and the tubule BMs, whereas the GBM stained less intensely (Figure 7) . Outside the kidney all BMs, including those of endothelia, epithelia, all types of muscle cells, and liver sinusoids, stained positively with these antibodies ( Table 2 ). These data suggest that there are (at least) two antigenically different types of BM HSPGs: a large HSPG present in all BMs and a small HSPG present in most epithelial and endothelial BMs but absent in the BMs of most types of muscle cells. Klein et al. (40) have suggested that the small HSPG is derived from the large HSPG by proteolysis. However, the differences in distribution patterns obtained with antibodies against either type of BM HSPG (Table 2; Figure 7 ) argue against this assumption and suggest that both types of BM HSPG are unrelated. Mohan and Spiro (54) also suggested this, since they found a limited crossreactivity between GBM HSPG and EHS HSPG. Moreover, Rada et al. (59) found different distribution patterns with anti-GBM HSPG than with anti-EHS HSPG antibodies within the GBM. Very recently, Soroka and Farquhar (70) described a novel HSPG produced by hepatocytes, which is present in the extracellular matrix of liver sinusoids and in BMs. Whether this type of HSPG represents a third type of BM HSPG remains to be elucidated. However, antibodies against this liver BM HSPG do not crossreact with GBM HSPG, and its staining pattern in kidney, liver, cardiac muscle, pancreas, and small intestine is identical to those observed with antibodies against EHS HSPG. Furt!ier experiments are needed to determine whether or not this novel liver BM HSPG is a member of the EHS HSPG family. At present it is not clear whether the I Figure 7 Indirect IF on human kidney cryostat section with MAb against (A) the large mouse EHS HSPG. which crossreact with human HSPG. or against (E) the small human GEM HSPG (MAb JM-72) Note the differences. especially in the glomerular staining pattern, in A predominantly mesangial staining and in B strong GEM staining. Bars = 50 pm.
BM HSPG diversity is due to differential processing of a common precursor, to differential splicing of mRNA. or to different genes encoding for HSPG. Conclusive data to solve this problem must come from cloning of the genes coding for the various core proteins of BM HSPGs. Very recently, the complete sequence of a human BM HSPG has been published (34). showing a great homology with the large mouse EHS HSPG called perlecan (56) . Future comparison of MAb raised against peptides encoded by different domains of perlecan with our MAb raised against GBM HSPG will provide some more conclusive data about the relationship between both types of HSPG. The tissue distribution of anti-GBM HSPG core protein MAb JM-72 is different from those observed with antibodies against core proteins of other PGs such as anti-BM chondroitin sulfate PG (52), anti-cell surface-associated HSPG (25), and anti-chondroitinIdermatan sulfate PG (84) .
With indirect IEM we also found that binding ofJM-72 in the human kidney was restricted to the various renal BMs, most prominently in the GBM. Interestingly, there was also some reaction product between the mesangium and the capillary endothelium. Since all other parts of the mesangium were negative, this suggests an endothelial origin of HSPG at this special location. Within the GBM the staining was most prominent at the endothelial side of the GBM. Using the same procedure (indirect immunoperoxidase) Stow et al. (72) also found the highest binding of anti-GBM HSPG antibodies in the lamina rara intema of the GBM. However, using different techniques (indirect immunogold on ultra-thin frozen sections or a direct immunoperoxidase procedure after IV injection of the antibodies), they localized HSPG in both laminae rara of the GBM (72). which was also found by Rada and Carlson (59) using the immunogold technique. Whether the unexpected staining pattern ofJM-72 is the result of a preferential expression in the lamina rara interna of the recognized HSPG epitope or of a lesser accessibility of these HSPG epitopes in the lamina rara externa is not yet known. An alternative explanation may be that the indirect immunoperoxidase technique we used is not sensitive enough to precisely localize antigens within layers of the GBM, as suggested previously (10) .
HS Distribution in Human Tissues
In indirect IF with MAb JM-403 on human kidney sections we demonstrated a finely granular to linear binding to the GBM and most other but not all renal BMs. This pattern is somewhat different from the JM-72 staining in the kidney, especially with respect to the tubule BM staining (see Figures 4B and 4D) . In contrast to JM-403. MAb JM-72 stained all tubule BMs, indicating that HSPG is present in all tubule BMs. Moreover, in a previous study (81) we were unable to demonstrate any differences between HSPG from tubule BM or GBM origin, suggesting that both molecules are identical. For that reason we think that the heterogeneity of tubule BM staining as observed for MAb JM-403 can be explained by variations in the macromolecular compositions of these BMs. HS-binding domains have been demonstrated on collagen Type IV, laminin, and fibronectin (74). It is conceivable that binding of the HS chains of HSPG to one or more of these BM components interferes with binding of MAb JM-403 to its epitope. Such a selective epitope expression or accessibility within BMs is not unique, since it has been described previously for another anti-HS MAb (78) and for other BM components such as laminin, S-laminin, merosin, and the NC1 segment of the different a-chains of collagen Type IV (1, 13, 29, 31, 41, 46, 64, 85) . Our finding, showing variable tubule BM staining with anti-HS MAb JM-403, confirms this concept of BM heterogeneity (11). This heterogeneity in BMs is also thought to be responsible for the subtle differences in staining patterns between both MAb observed in the tissues tested in this study ( Table 1) .
The indirect IEM showed mainly binding of MAb JM-403 to the inner side of the GBM. This staining pattem does not correspond to the distribution pattern of cationic probes, which detect regularly arranged clusters of anionic sites in both laminae rarae of the GBM (36). Although HS is thought to be a major determinant of anionic sites in the GBM, other molecules are also involved (2,73), which may explain the difference. Another possibility is that the JM-403 epitope is preferentially expressed in the lamina rara interna of the GBM. Although MAb JM-72 stained predominantly the lamina rara intema. it also stained the other layers ofthe GBM, in contrast to MAb JM-403. Since both MAb belong to different isotypes (IgG1 vs IgM), this difference may be due to differences in tissue penetration. Alternatively, the relative absence of staining at the outer side of the GBM by both MAb could be the result of the cold ischemia time and/or the absence of fluid flow across the GBM of the cadaver kidney used in these experiments.
The HS epitope recognized by MAb JM-403 is present in most BMs throughout the body. SinceJM-403 bound to the GBM as well as to basal laminae of all muscle cell types and liver sinusoids, it recognizes an HS epitope carried by both suggested types of BM HSPG. This idea is further substantiated by our fmding that MAb JM-403 bound equally well in ELISA to purified GBM HSPG (the small HSPG) as to the large HSPG purified from the mouse EHS tumor, whereas antibodies against the core protein of GBM HSPG (polyclonal and MAb) bound to GBM HSPG but did not recognize the EHS HSPG (unpublished observations).
Although MAb against HS have been described (44,68) they were not used for tissue distribution studies of HS by immunohistochemical methods. Comparison of the distribution of anti-HS MAb JM-403 with the findings of others, using MAb against chondroitin sulfate (8) , dermatan sulfate (69), and keratan sulfate (87), confirmed the uniqueness and HS specificity of MAb JM-403.
Antibodies recognizing different epitopes of the HSPG molecule can be of value in elucidation of the function of HSPG in human BM assembly and function, as well as its role in many pathological conditions, such as tumor invasion, and several renal diseases such as diabetic nephropathy (57, 67) , the congenital nephrotic syndrome (79, 83) , and adult polycystic kidney disease (5).
